Takashi Tsukamoto, Ph.D.

Headshot of Takashi Tsukamoto
  • Director, Medicinal Chemistry, Johns Hopkins Drug Discovery Program
  • Professor of Neurology

Research Interests

Drug Discovery

Background

Takashi Tsukamoto, Ph.D. is Associate Professor of Neurology at Johns Hopkins University and the Director of Medicinal Chemistry at Johns Hopkins Drug Discovery Program. Dr. Tsukamoto received his Ph.D. degree in Chemistry from Tokyo Institute of Technology and pursued postdoctoral studies in the Department of Medicinal Chemistry at the University of Michigan. Prior to joining Johns Hopkins in 2009, Dr. Tsukamoto has held a variety of research positions in the pharmaceutical industry including Guilford Pharmaceuticals, MGI Pharma, and the Eisai Research Institute. During the course of his career, he has served as a lead medicinal chemist in a number of drug discovery projects exploring new therapeutics for neurological disorders and cancer. At the Johns Hopkins Drug Discovery Program, Dr. Tsukamoto leads a team of medicinal chemists involved in the design and synthesis of small molecules of therapeutic significance in various projects.

...read more

Titles

  • Director, Medicinal Chemistry, Johns Hopkins Drug Discovery Program
  • Professor of Neurology
  • Professor of Pharmacology and Molecular Sciences

Departments / Divisions

Centers & Institutes

Education

Degrees

  • B.S.; Tokyo Institute of Technology (Japan) (1993)
  • Ph.D.; Tokyo Institute of Technology (Japan) (1993)

Additional Training

  • University of Michigan, Ann Arbor, Michigan, 1997, Medicinal Chemistry

Research & Publications

Research Summary

Medicinal chemistry in the areas of neurological disorders and cancer

Selected Publications

View all on PubMed

Design, synthesis, and pharmacological evaluation of fluorinated tetrahydrouridine derivatives as inhibitors of cytidine deaminase. Ferraris D, Duvall B, Delahanty G, Mistry B, Alt J, Rojas C, Rowbottom C, Sanders K, Schuck E, Huang KC, Redkar S, Slusher BB, Tsukamoto T. J Med Chem. 2014 Mar 27;57(6):2582-8. doi: 10.1021/jm401856k. Epub 2014 Feb 24. PMID: 24520856

δ-Thiolactones as prodrugs of thiol-based glutamate carboxypeptidase II (GCPII) inhibitors. Ferraris DV, Majer P, Ni C, Slusher CE, Rais R, Wu Y, Wozniak KM, Alt J, Rojas C, Slusher BS, Tsukamoto T. J Med Chem. 2014 Jan 9;57(1):243-7. doi: 10.1021/jm401703a. Epub 2013 Dec 27. PMID: 24354364

MrgC agonism at central terminals of primary sensory neurons inhibits neuropathic pain. He SQ, Li Z, Chu YX, Han L, Xu Q, Li M, Yang F, Liu Q, Tang Z, Wang Y, Hin N, Tsukamoto T, Slusher B, Tiwari V, Shechter R, Wei F, Raja SN, Dong X, Guan Y. Pain. 2014 Mar;155(3):534-44. doi: 10.1016/j.pain.2013.12.008. Epub 2013 Dec 11. PMID: 24333779

Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations. Emadi A, Jun SA, Tsukamoto T, Fathi AT, Minden MD, Dang CV. Exp Hematol. 2014 Apr;42(4):247-51. doi: 10.1016/j.exphem.2013.12.001. Epub 2013 Dec 11. PMID: 24333121

Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis. Rojas C, Raje M, Tsukamoto T, Slusher BS. Eur J Pharmacol. 2014 Jan 5;722:26-37. doi: 10.1016/j.ejphar.2013.08.049. Epub 2013 Oct 31. PMID: 24184669

Contact for Research Inquiries

855 North Wolfe Street, Suite 231
Baltimore, MD 21205-1503 map
Phone: 410-614-0982

Email me

Academic Affiliations & Courses

Courses and Syllabi

  • Introduction to Drug Discovery Research (ME:200.704)
  • Drug Discovery Case Studies (ME:200.707)

Activities & Honors

Honors

  • Ichikizaki Fund for Young Chemists, Chemical Society of Japan, 1992
  • Ikueikai Scholarship, 1992
  • Tejima Award for Distinguished Ph.D. Thesis, Tokyo Institute of Technology, 1994

Memberships

  • American Chemical Society, 1994

Professional Activities

  • Chair, Maryland Section of the American Chemical Society, 2011
  • Director, Medicinal Chemistry MGI Pharma, 2006 - 2008
  • Director, Medicinal Chemistry Eisai Research Institute, 2008 - 2009
  • Director, Chemistry and Intellectual Property Brain Science Institute, 2009
  • Editor-in-Chief, Chesapeake Chemist, 2011
  • Principal Scientist I, Medicinal Chemistry Guilford Pharmaceuticals Inc., 2005 - 2005
  • Reviewer, Journal of Medicinal Chemistry
  • Reviewer, Journal of Biological Chemistry
  • Reviewer, Journal of Organic Chemistry
  • Reviewer, Bioorganic Medicinal Chemistry
  • Reviewer, Bioorganic Medicinal Chemistry Letters
  • Reviewer, Open Medicinal Chemistry Journal
  • Mentor, Incentive Mentoring Program, 2010
  • Project SEED Coordinator, 2011 - 2011

Videos & Media

Lectures and Presentations

  • The regioselective nucleophilic reactions of 4,4-difluoroglutamic acid diester and synthetic applications
    210th ACS National Meeting, Chicago, IL (01/20/1995)
  • Design, Synthesis and Biological Activity of NAALADase Inhibitors
    Pacifichem 2000, Honolulu, Hawaii (01/14/2000)
  • Inhibition of Glutamate Carboxypeptidase II: A novel approach to reduce glutamate excitotoxicity
    International Conference on Protease Inhibitors, Nagoya, Japan (01/13/2003)
  • Role of NAAG in Neuroprotection
    First International Symposium on N-Acetylaspartate (Canavan Disease), Bethesda, MD (01/14/2004)
  • Therapeutic Utility of GCP II (NAALADase) Inhibitors in Neurodegenerative diseases
    GTCbio 2nd Annual conference on Therapeutic Strategies against Neurodegenerative Conditions (TSANC), Washington, DC (01/19/2006)
  • The Johns Hopkins Brain Science Institute Translational Program: Discovering Treatments for Brain Disorders
    Nashville, TN (01/10/2009)
    Vanderbilt University
  • Brain, Drugs, and Chemistry
    Shizuoka, Japan (01/29/2009)
    K.I Chemical Research Institute
  • Academic Drug Discovery Efforts in USA
    RaQualia Pharma, Aichi, Japan (01/30/2009)
  • Medicinal chemistry of D-amino acid oxidase inhibitors
    Chiba, Japan (01/16/2010)
    Chiba University School of Medicine
  • Discovery of D-amino acid oxidase Inhibitors as new therapeutics for schizophrenia
    Aichi, Japan (01/22/2010)
    Nagoya University School of Medicine
  • Drug Discovery in Academia
    Ibaraki, Japan (01/26/2010)
    Eisai Tsukuba Research Laboratories
  • Discovery of D-amino acid oxidase Inhibitors as new therapeutics for schizophrenia
    Tokyo, Japan (01/03/2010)
    National Center of Neurology and Psychiatry
  • Career in Chemistry, Challenges and Opportunities
    Baltimore, Maryland (01/29/2010)
    College of Notre Dame of Maryland
  • Novel therapeutics for schizophrenia
    Joint meeting of the Johns Hopkins University Alliance for Science and Technology Development and the University of Maryland., Baltimore, Maryland (01/04/2010)
  • Discovery of D-amino acid oxidase Inhibitors as new therapeutics for schizophrenia
    Tokushima, Japan (01/11/2011)
    University of Tokushima School of Medicine
  • Discovery of D-amino acid oxidase Inhibitors as new therapeutics for schizophrenia
    Tokyo, Japan (01/12/2011)
    Otsuka Pharmaceutical
  • Discovery of D-amino acid oxidase Inhibitors as new therapeutics for schizophrenia
    Tokyo, Japan (01/12/2011)
    Asubio Pharma
  • Drug discovery research at the intersection of chemistry and biology
    STEM Scholars STEP Up Summer Program, Belair, Maryland (01/01/2011)
    Harford Community College
  • Drug discovery research at the intersection of chemistry and biology
    Baltimore, Maryland (01/22/2011)
    Morgan State University
  • Drug discovery research at the intersection of chemistry and biology
    Baltimore, Maryland (01/16/2011)
    CCBC Society of STEM Scholars
Is this you? Edit Profile
back to top button